Glaukos Corp., a specialist in minimally invasive glaucoma surgery, enjoyed an over-40% boost in its share price after its much bigger MIGS rival, the eyecare giant Alcon Inc., announced it was pulling all its CyPass microstents off the shelves.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?